Categories: Business

RNA drug developer ADARx seeks $1.74 billion valuation in US IPO

Sept 21 (Reuters) – ADARx Pharmaceuticals is targeting a valuation of up to $1.74 billion in its US initial public offering, the company developing RNA drugs said on Monday. The ‌company is aiming to

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Indianews Syndication

Recent Posts

NC State outscores ETSU by 24 points in home stretch, foils upset bid

Despite a slow start, NC State fended off East Tennessee State's upset bid on Friday…

3 minutes ago

Russian aide and military intelligence chief to attend talks with US and Ukraine, Kremlin says

Nov 7 (Reuters) - Russia's delegation to talks with the United States and Ukraine next…

9 minutes ago

UPDATE 4-New Zealand election early count shows two main parties near deadlocked

(Updates vote count, adds Seymour quote, paragraphs 1-5) By Lucy Craymer and Alasdair Pal WELLINGTON,…

14 minutes ago

Ohio State dominates second half, pulls away from Youngstown State

John Mobley Jr. scored 25 points while Andrija Jelavic and Amare Bynum keyed a second-half…

20 minutes ago